{"title":"通过人类乳头瘤病毒疫苗接种和宫颈筛查计划预防宫颈癌","authors":"Mark McGowan, Peter Otott","doi":"10.1016/j.ogrm.2023.11.001","DOIUrl":null,"url":null,"abstract":"<div><p><span>Cervical cancer causes more than 300,000 deaths worldwide every year, affecting women from a young age. It has a well-understood natural history, caused by HPV, which is estimated to be responsible for 99.8% of cases. In order to decrease the number of UK cervical cancer cases, a national screening programme was launched in 1988. Women between the ages of 25 and 64 are invited for </span>cervical screening<span>. A primary high-risk HPV testing approach is used, whereby samples are only tested for cytology<span><span> if they are positive for high-risk HPV. The national HPV vaccination programme was introduced in 2008 in the UK. The Gardasil 9 vaccine is offered at year 8 in UK schools (ages 12–13 years old) to boys and girls. These programmes have been a huge success in reducing the number of cervical cancer cases. However, still only 70% of eligible women attend their screening appointments. To further increase the proportion of women reached by the programme, further alternatives are currently tested, including home vaginal swab tests and </span>urinary HPV testing.</span></span></p></div>","PeriodicalId":53410,"journal":{"name":"Obstetrics, Gynaecology and Reproductive Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preventing cervical cancer through human papillomavirus vaccination and cervical screening programmes\",\"authors\":\"Mark McGowan, Peter Otott\",\"doi\":\"10.1016/j.ogrm.2023.11.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Cervical cancer causes more than 300,000 deaths worldwide every year, affecting women from a young age. It has a well-understood natural history, caused by HPV, which is estimated to be responsible for 99.8% of cases. In order to decrease the number of UK cervical cancer cases, a national screening programme was launched in 1988. Women between the ages of 25 and 64 are invited for </span>cervical screening<span>. A primary high-risk HPV testing approach is used, whereby samples are only tested for cytology<span><span> if they are positive for high-risk HPV. The national HPV vaccination programme was introduced in 2008 in the UK. The Gardasil 9 vaccine is offered at year 8 in UK schools (ages 12–13 years old) to boys and girls. These programmes have been a huge success in reducing the number of cervical cancer cases. However, still only 70% of eligible women attend their screening appointments. To further increase the proportion of women reached by the programme, further alternatives are currently tested, including home vaginal swab tests and </span>urinary HPV testing.</span></span></p></div>\",\"PeriodicalId\":53410,\"journal\":{\"name\":\"Obstetrics, Gynaecology and Reproductive Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrics, Gynaecology and Reproductive Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1751721423001872\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrics, Gynaecology and Reproductive Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1751721423001872","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Preventing cervical cancer through human papillomavirus vaccination and cervical screening programmes
Cervical cancer causes more than 300,000 deaths worldwide every year, affecting women from a young age. It has a well-understood natural history, caused by HPV, which is estimated to be responsible for 99.8% of cases. In order to decrease the number of UK cervical cancer cases, a national screening programme was launched in 1988. Women between the ages of 25 and 64 are invited for cervical screening. A primary high-risk HPV testing approach is used, whereby samples are only tested for cytology if they are positive for high-risk HPV. The national HPV vaccination programme was introduced in 2008 in the UK. The Gardasil 9 vaccine is offered at year 8 in UK schools (ages 12–13 years old) to boys and girls. These programmes have been a huge success in reducing the number of cervical cancer cases. However, still only 70% of eligible women attend their screening appointments. To further increase the proportion of women reached by the programme, further alternatives are currently tested, including home vaginal swab tests and urinary HPV testing.
期刊介绍:
Obstetrics, Gynaecology and Reproductive Medicine is an authoritative and comprehensive resource that provides all obstetricians, gynaecologists and specialists in reproductive medicine with up-to-date reviews on all aspects of obstetrics and gynaecology. Over a 3-year cycle of 36 issues, the emphasis of the journal is on the clear and concise presentation of information of direct clinical relevance to specialists in the field and candidates studying for MRCOG Part II. Each issue contains review articles on obstetric and gynaecological topics. The journal is invaluable for obstetricians, gynaecologists and reproductive medicine specialists, in their role as trainers of MRCOG candidates and in keeping up to date across the broad span of the subject area.